减少围绕阿尔茨海默氏症和痴呆症专家概念的混:一个实际的分析
Timothy Daly1,2, Ignacio Mastroleo2,3
1Bordeaux Population Health CNRS UMR 1219, University of Bordeaux and INSERM, Bordeaux, France.
Journal of neuropsychology
|October 25, 2024
概括
对于阿尔茨海默病 (AD) 和相关痴呆症的新诊断标准可能会引起混乱. 卫生保健工作者和公众需要进行社会伦理干预,以澄清这些标准并防止伤害.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 医学伦理 医学伦理
背景情况:
- 对阿尔茨海默病 (AD) 和相关痴呆症存在多种,有时相互矛盾的概念化.
- 这些不同的观点在医疗保健和研究中具有不同的实际目的.
- 新的和旧的诊断标准的共存,以及阿尔茨海默病的耻辱,可能会导致严重的误解.
研究的目的:
- 解决因AD的不同诊断标准而产生的误解和伤害的可能性.
- 倡导阐明当代诊断方法的干预措施.
- 弥合老年痴呆症的确立和新兴诊断框架之间的差距.
主要方法:
- 这是一篇评论文章,而不是经验研究.
- 作者分析了当前阿尔茨海默病诊断标准的影响.
- 重点是提出社会伦理干预措施.
主要成果:
- 目前阿尔茨海默病诊断的情况存在混和潜在危害的风险.
- 现有的诊断标准可以被专业人士和公众都认为是不确定的.
- 需要对诊断标准进行明确的沟通.
结论:
- 社会伦理干预对于医疗保健专业人员和公众来说至关重要.
- 这些干预措施应该旨在减少围绕当代AD诊断标准的不确定性.
- 阐明新标准与既定标准之间的关系对于准确的理解和关心至关重要.
相关概念视频
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Dementia
108
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
108
Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
Cognitive Development During Adulthood
72
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
72
Cognitivism
1.4K
Cognitive psychology emerged as a significant field in the mid-20th century. It focused on understanding humans' internal mental processes. This approach emphasizes how people perceive, remember, think, and solve problems—elements critical to human cognition.
Previously dominated by behaviorism, which prioritized observable behaviors and largely ignored mental processes, psychology transformed in the 1950s. Cognitive psychologists argue that understanding how we think and process...
Previously dominated by behaviorism, which prioritized observable behaviors and largely ignored mental processes, psychology transformed in the 1950s. Cognitive psychologists argue that understanding how we think and process...
1.4K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
111
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
111


